# Orthofix Medical Inc.: Form 10-Q for the period ended Sep 30, 2022

- Company: [Orthofix Medical Inc.](/companies/ofix.md) (CIK 884624)
- Form: 10-Q
- Filed: 2022-11-03
- Accepted by EDGAR: Nov 3, 2022, 07:13 ET
- Period: 2022-09-30
- Accession: 0000950170-22-021538
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/884624/000095017022021538/ofix-20220930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/884624/000095017022021538/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-07-01 to 2022-09-30 | $114.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2022-01-01 to 2022-09-30 | $338.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2022-07-01 to 2022-09-30 | $30.6m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2022-01-01 to 2022-09-30 | $90.5m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2022-07-01 to 2022-09-30 | $83.4m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2022-01-01 to 2022-09-30 | $248.0m | us-gaap:GrossProfit |
| Research and development | 3 months, 2022-07-01 to 2022-09-30 | $11.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2022-01-01 to 2022-09-30 | $35.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2022-07-01 to 2022-09-30 | −$5.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2022-01-01 to 2022-09-30 | −$2.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2022-07-01 to 2022-09-30 | $1.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2022-01-01 to 2022-09-30 | $2.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-07-01 to 2022-09-30 | −$10.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2022-01-01 to 2022-09-30 | −$12.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-07-01 to 2022-09-30 | −$0.53 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2022-01-01 to 2022-09-30 | −$0.63 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-07-01 to 2022-09-30 | −$0.53 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2022-01-01 to 2022-09-30 | −$0.63 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-07-01 to 2022-09-30 | 20,091 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2022-01-01 to 2022-09-30 | 20,007 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2022-01-01 to 2022-09-30 | −$13.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2022-01-01 to 2022-09-30 | $16.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-09-30 | $51.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-09-30 | $246.9m | us-gaap:AssetsCurrent |
| Total assets | at 2022-09-30 | $449.7m | us-gaap:Assets |
| Current liabilities | at 2022-09-30 | $77.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-09-30 | $116.1m | us-gaap:Liabilities |
| Shareholders' equity | at 2022-09-30 | $333.5m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 30,943 characters.

The following discussion and analysis of Orthofix Medical Inc.’s (sometimes referred to as “we,” “us” or “our”) financial condition and results of our operations should be read in conjunction with the “Forward-Looking Statements” and our condensed consolidated financial statements and related notes thereto appearing elsewhere in this Form 10-Q.

### Executive Summary

We are a global medical device company with a spine and orthopedics focus. Our mission is to deliver innovative, quality-driven solutions as we partner with health care professionals to improve patient mobility. Headquartered in Lewisville, Texas, our spine and orthopedic products are distributed in more than 60 countries via our sales representatives and distributors. For more information, please visit www.Orthofix.com.

Notable financial metrics in the third quarter of 2022 and recent achievements include the following:

- Net sales of $114.0 million, an increase of 1% on a reported basis and 5% on a constant currency basis over prior year
- Global Orthopedics net sales growth of 19% on a constant currency basis driven by new product and channel investments
- Orthofix and MTF Biologics recognized with the 2022 Spine Technology Award from Orthopedics This Week for Virtuos Lyograft, the first of its kind, shelf-stable and complete autograft substitute
- Announced agreement to merge with SeaSpine, creating a leading global spine and orthopedics company

### Results of Operations

The following table provides certain items in our condensed consolidated statements of operations as a percent of net sales:

|  | Three Months Ended September 30, 2022 (%) | 2021 (%) | Nine Months Ended September 30, 2022 (%) | 2021 (%) |
| --- | ---: | ---: | ---: | ---: |
| Net sales | 100.0 | 100.0 | 100.0 | 100.0 |
| Cost of sales | 26.8 | 25.2 | 26.7 | 24.1 |
| Gross profit | 73.2 | 74.8 | 73.3 | 75.9 |
| Sales and marketing | 48.7 | 49.9 | 50.1 | 48.4 |
| General and administrative | 16.9 | 14.5 | 16.1 | 15.1 |
| Research and development | 10.5 | 11.0 | 10.6 | 10.7 |
| Acquisition-related amortization and remeasurement | 2.2 | (0.3) | (2.8) | 1.4 |
| Operating income (loss) | (5.1) | (0.3) | (0.7) | 0.3 |
| Net loss | (9.4) | (1.9) | (3.7) | (1.6) |

### Net Sales by Product Category and Reporting Segment

The following tables provide net sales by major product category by reporting segment:

*(U.S. Dollars, in thousands)*

|  | Three Months Ended September 30, 2022 | 2021 | Percentage Change Reported | Constant Currency |
| --- | ---: | ---: | ---: | ---: |
| Bone Growth Therapies | $46,531 | $45,168 | 3.0% | 3.0% |
| Spinal Implants | 25,857 | 28,151 | -8.1% | -7.1% |
| Biologics | 13,798 | 12,806 | 7.7% | 7.7% |
| Global Spine | 86,186 | 86,125 | 0.1% | 0.4% |
| Global Orthopedics | 27,810 | 26,303 | 5.7% | 19.0% |
| Net sales | $113,996 | $112,428 | 1.4% | 4.8% |

18

*(U.S. Dollars, in thousands)*

|  | Nine Months Ended September 30, 2022 | 2021 | Percentage Change Reported | Constant Currency |
| --- | ---: | ---: | ---: | ---: |
| Bone Growth Therapies | $136,244 | $137,821 | -1.1% | -1.1% |
| Spinal Implants | 80,693 | 83,943 | -3.9% | -3.0% |
| Biologics | 42,686 | 41,351 | 3.2% | 3.2% |
| Global Spine | 259,623 | 263,115 | -1.3% | -1.1% |
| Global Orthopedics | 78,861 | 76,300 | 3.4% | 12.7% |
| Net sales | $338,484 | $339,415 | -0.3% | 2.0% |

Global Spine

Global Spine offers the following Product categories:

- Bone Growth Therapies, which manufactures, distributes, sells, and provides support services for market leading devices that enhance bone fusion. Bone Growth Therapies uses distributors and sales representatives to sell its devices and provide associated services to hospitals, healthcare providers, and patients.
- Spinal Implants, which designs, develops and markets a broad portfolio of motion preservation and spine fixation implant products used in surgical procedures of the spine. Spinal Implants distributes its products globally through a network of distributors and sales representatives to sell spine products to hospitals and healthcare providers.
- Biologics, which provides a portfolio of regenerative products and tissue forms that allow physicians to successfully treat a variety of spinal and orthopedic conditions. Biologics markets its tissues to hospitals and healthcare providers, primarily in the U.S., through a network of employed and independent sales representatives.

#### Three months ended September 30, 2022 compared to 2021

Net sales of $86.2 million, an increase of $0.1 million or 0.1%

- Bone Growth Therapies net sales increased $1.4 million or 3.0%, largely driven by the successful commercial roll-out of our AccelStim Bone Healing Therapy, which was launched late in the second quarter of 2022, and higher order volumes
- Spinal Implants net sales decreased $2.3 million or 8.1%, primarily due to a change in procedure mix in the U.S. for Spinal Fixation, large international orders in 2021 that did not reoccur, as well as global competitive headwinds in Motion Preservation
- Biologics net sales increased $1.0 million or 7.7%, driven by successful new product introductions, such as FiberFuse and Virtuos

#### Nine months ended September 30, 2022 compared to 2021

Net sales of $259.6 million, a decrease of $3.5 million or 1.3%

- Bone Growth Therapies net sales decreased $1.6 million or 1.1%, primarily driven by a continued slowdown in complex procedure volumes due to hospital restrictions at the beginning of the year and continued staffing issues, which impacted complex spine procedures, partially offset by the successful commercial roll-out of our AccelStim Bone Healing Therapy in 2022
- Spinal Implants net sales decreased $3.3 million or 3.9%, primarily due to a change in procedure mix in the U.S. for Spinal Fixation, lower-than-expected complex procedures case volumes earlier in the year, as well as global competitive headwinds in Motion Preservation
- Biologics net sales increased $1.3 million or 3.2%, driven by successful new product introductions, such as FiberFuse and Virtuos

Global Orthopedics

Global Orthopedics offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions specifically related to limb reconstruction and deformity correction unrelated to the spine. Global Orthopedics distributes its products globally through a network of distributors and sales representatives to sell orthopedic products to hospitals and healthcare providers.

#### Three months ended September 30, 2022 compared to 2021

Net sales of $27.8 million, an increase of $1.5 million or 5.7%

- Double-digit growth in the U.S. and internationally on a constant currency basis from strategic investments in our commercial channels and momentum from new product introductions
- Partially offset by a decrease of $3.5 million due to movement in foreign currency exchange rates

#### Nine months ended September 30, 2022 compared to 2021

Net sales of $78.9 million, an increase of $2.6 million or 3.4%

- Double-digit growth internationally on a constant currency basis paired with solid growth in the U.S. from strategic investments in our commercial channels and momentum from new product introductions
- Partially offset by a decrease of $7.1 million due to movement in foreign currency exchange rates

### Gross Profit

*(U.S. Dollars, in thousands)*

|  | Three Months Ended September 30, 2022 | 2021 | % Change | Nine Months Ended September 30, 2022 | 2021 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net sales | $113,996 | $112,428 | 1.4% | $338,484 | $339,415 | (0.3%) |
| Cost of sales | 30,573 | 28,307 | 8.0% | 90,491 | 81,660 | 10.8% |
| Gross profit | $83,423 | $84,121 | (0.8%) | $247,993 | $257,755 | (3.8%) |
| Gross margin | 73.2% | 74.8% | (1.6%) | 73.3% | 75.9% | -2.7% |

#### Three months ended September 30, 2022 compared to 2021

Gross profit decreased $0.7 million

- Decrease in gross profit driven primarily by increased inventory reserves related to set builds to support an expanding sales force and increased safety stock requirements driven by the risk of global supply chain disruption
- Decrease also driven by unfavorable changes in shipping costs, increased manufacturing overhead costs, and unfavorable movements in foreign currency exchange rates
- Partially offset by favorable changes in sales mix

#### Nine months ended September 30, 2022 compared to 2021

Gross profit decreased $9.8 million

- Decrease in gross profit driven primarily by changes in our sales mix as well increased inventory reserves related to set builds for an expanding sales force and increased safety stock requirements driven by the risk of global supply chain disruption
- Decrease also driven by unfavorable changes in shipping costs, increased manufacturing overhead costs, and unfavorable movements in foreign currency exchange rates

### Sales and Marketing Expense

*(U.S. Dollars, in thousands)*

|  | Three Months Ended September 30, 2022 | 2021 | % Change | Nine Months Ended September 30, 2022 | 2021 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Sales and marketing | $55,461 | $56,097 | (1.1%) | $169,486 | $164,220 | 3.2% |
| As a percentage of net sales | 48.7% | 49.9% | (1.2%) | 50.1% | 48.4% | 1.7% |

20

#### Three months ended September 30, 2022 compared to 2021

Sales and marketing expense decreased $0.6 million

- Decrease of $1.8 million attributable to differences in the timing of certain sales meetings and conferences in 2022 as compared to 2021
- Partially offset by an increase of $0.9 million in commission expenses, largely resulting from changes in sales volume and sales mix

#### Nine months ended September 30, 2022 compared to 2021

Sales and marketing expense increased $5.3 million

- Significant increases in travel, sales events, and surgeon and sales education trainings as in-person events have largely resumed in 2022
- Significant increase also attributable to the hiring of additional sales and marketing headcount to support growth and initiatives across all product lines

### General and Administrative Expense

*(U.S. Dollars, in thousands)*

|  | Three Months Ended September 30, 2022 | 2021 | % Change | Nine Months Ended September 30, 2022 | 2021 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| General and administrative | $19,322 | $16,312 | 18.5% | $54,496 | $51,091 | 6.7% |
| As a percentage of net sales | 16.9% | 14.5% | 2.4% | 16.1% | 15.1% | 1.0% |

#### Three months ended September 30, 2022 compared to 2021

General and administrative expense increased $3.0 million

- Increase of $2.6 million on strategic investments, primarily attributable to due diligence and deal-related costs related to the pending merger with SeaSpine
- Increase of $0.8 million in share-based compensation expenses as the tenure of our new management team increases
- Partially offset by a decrease in other compensation costs, partly stemming from the departure of certain former executives and from macroeconomic pressures on certain variable compensation expenses

#### Nine months ended September 30, 2022 compared to 2021

General and administrative expense increased $3.4 million

- Increase of $3.0 million on strategic investments, primarily attributable to due diligence and deal-related costs related to the pending merger with SeaSpine
- Increase of $1.8 million in share-based compensation expenses as the tenure of our new management team increases
- Partially offset by a decrease in other compensation costs, partly stemming from the departure of certain former executives and from macroeconomic pressures on certain variable compensation expenses

### Research and Development Expense

*(U.S. Dollars, in thousands)*

|  | Three Months Ended September 30, 2022 | 2021 | % Change | Nine Months Ended September 30, 2022 | 2021 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $11,943 | $12,360 | (3.4%) | $35,913 | $36,378 | (1.3%) |
| As a percentage of net sales | 10.5% | 11.0% | (0.5%) | 10.6% | 10.7% | (0.1%) |

#### Three months ended September 30, 2022 compared to 2021

Research and development expense decreased $0.4 million

- Decrease in integration activities attributable to certain recent asset acquisitions, as well as a decline in costs associated with certain clinical studies
- Partially offset by an increase related to costs to comply with the European Union Medical Device Regulations and increases in new product development expenses

#### Nine months ended September 30, 2022 compared to 2021

Research and development expense decreased $0.5 million

- Decrease of $0.8 million related to the attainment of a development milestone with MTF Biologics achieved in 2021 that did not recur in 2022
- Decrease in integration activities attributable to certain recent asset acquisitions
- Partially offset by an increase related to costs to comply with the European Union Medical Device Regulations and increases in new product development expenses

### Acquisition-related Amortization and Remeasurement

*(U.S. Dollars, in thousands)*

|  | Three Months Ended September 30, 2022 | 2021 | % Change | Nine Months Ended September 30, 2022 | 2021 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Acquisition-related amortization and remeasurement | $2,484 | $(335) | (841.5%) | $(9,678) | $5,028 | (292.5%) |
| As a percentage of net sales | 2.2% | (0.3%) | 2.5% | (2.9%) | 1.4% | (4.3%) |

Acquisition-related amortization and remeasurement consists of (i) amortization related to intangible assets acquired through business combinations or asset acquisitions, (ii) remeasurement of any related contingent consideration arrangement, and (iii) recognized costs associated with acquired in-process research and development assets, which are recognized immediately upon acquisition.

#### Three months ended September 30, 2022 compared to 2021

Acquisition-related amortization and remeasurement increased $2.8 million

- Increase of $1.4 million in costs associated with acquired in-process research and development assets, which are recognized immediately upon acquisition, related to our License and Distribution Agreement with CGBio Co., Ltd.
- Increase of $1.3 million related to the remeasurement of potential revenue-based milestone payments associated with the Spinal Kinetics acquisition as we recorded a benefit of $1.0 million in 2022 compared to a benefit of $2.3 million in 2021

#### Nine months ended September 30, 2022 compared to 2021

Acquisition-related amortization and remeasurement decreased $14.7 million

- Decrease of $15.2 million related to the remeasurement of potential revenue-based milestone payments associated with the Spinal Kinetics acquisition, as we do not expect to achieve the remaining revenue-based milestone prior to April 30, 2023, based on current net sales trends
- Partially offset by an increase of $0.4 million associated with the reassessment of contingent consideration associated with the acquisition of a former distributor recognized in 2021

### Non-operating Income and Expense

*(U.S. Dollars, in thousands)*

|  | Three Months Ended September 30, 2022 | 2021 | % Change | Nine Months Ended September 30, 2022 | 2021 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest expense, net | $(277) | $(433) | (36.0%) | $(1,059) | $(1,400) | (24.4%) |
| Other expense, net | (3,308) | (1,789) | 84.9% | (7,436) | (3,528) | 110.8% |

#### Three months ended September 30, 2022 compared to 2021

Other expense, net increased $1.5 million

- Increase in expense primarily associated with movements in foreign currency exchange rates and the resulting gains and/or losses recorded in each period, with the change primarily attributable to the strengthening of the U.S. Dollar against the Euro in 2022

#### Nine months ended September 30, 2022 compared to 2021

Other expense, net increased $3.9 million

- Increase in expense primarily associated with movements in foreign currency exchange rates and the resulting gains and/or losses recorded in each period, with the change primarily attributable to the strengthening of the U.S. Dollar against the Euro in 2022

### Income Taxes

*(U.S. Dollars, in thousands)*

|  | Three Months Ended September 30, 2022 | 2021 | % Change | Nine Months Ended September 30, 2022 | 2021 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Income tax expense | $1,344 | $(364) | (469.2%) | $1,968 | $1,677 | 17.4% |
| Effective tax rate | (14.3%) | 14.4% | (28.7%) | (18.4%) | (43.1%) | 24.7% |

#### Three months ended September 30, 2022 compared to 2021

- Increase in tax expense compared to the prior year period was primarily a result of changes in valuation allowances

#### Nine months ended September 30, 2022 compared to 2021

- Increase in tax expense compared to the prior year period was primarily a result of changes in valuation allowances

### Segment Review

Our business is managed through two reporting segments: Global Spine and Global Orthopedics. The primary metric used in managing the business by segment is EBITDA (which is described further in Note 10 to the Notes to the Unaudited Condensed Consolidated Financial Statements contained herein). The following table presents EBITDA by segment and reconciles consolidated EBITDA to loss before income taxes:

*(U.S. Dollars, in thousands)*

|  | Three Months Ended September 30, 2022 | 2021 | Nine Months Ended September 30, 2022 | 2021 |
| --- | ---: | ---: | ---: | ---: |
| Global Spine | $10,116 | $13,908 | $46,775 | $44,835 |
| Global Orthopedics | (473) | (196) | (5,991) | (650) |
| Corporate | (11,168) | (8,663) | (28,846) | (24,522) |
| Total EBITDA | $(1,525) | $5,049 | $11,938 | $19,663 |
| Depreciation and amortization | (7,570) | (7,151) | (21,598) | (22,153) |
| Interest expense, net | (277) | (433) | (1,059) | (1,400) |
| Loss before income taxes | $(9,372) | $(2,535) | $(10,719) | $(3,890) |

### Liquidity and Capital Resources

Cash and cash equivalents at September 30, 2022, totaled $51.7 million compared to $87.8 million at December 31, 2021.

*(U.S. Dollars, in thousands)*

|  | Nine Months Ended September 30, 2022 | 2021 | Change |
| --- | ---: | ---: | ---: |
| Net cash from operating activities | $(13,886) | $6,696 | $(20,582) |
| Net cash from investing activities | (18,634) | (14,031) | (4,603) |
| Net cash from financing activities | (1,576) | (5,673) | 4,097 |
| Effect of exchange rate changes on cash | (2,091) | (598) | (1,493) |
| Net change in cash and cash equivalents | $(36,187) | $(13,606) | $(22,581) |

The following table presents free cash flow, a non-GAAP financial measure, which is calculated by subtracting capital expenditures from net cash from operating activities:

*(U.S. Dollars, in thousands)*

|  | Nine Months Ended September 30, 2022 | 2021 | Change |
| --- | ---: | ---: | ---: |
| Net cash from operating activities | $(13,886) | $6,696 | $(20,582) |
| Capital expenditures | (17,260) | (12,781) | (4,479) |
| Free cash flow | $(31,146) | $(6,085) | $(25,061) |

23

### Operating Activities

Cash flows from operating activities decreased $20.6 million

- Decrease in net income of $7.1 million
- Net decrease of $13.6 million for non-cash gains and losses, largely related to changes in the fair value of contingent consideration
- Net decrease of less than $0.1 million relating to changes in working capital accounts, primarily attributable to changes in inventories, accounts payable, prepaid expenses and other current assets, and the payment of a contingent consideration milestone in the prior year

Two of our primary working capital accounts are accounts receivable and inventory. Days sales in receivables were 61 days at September 30, 2022, compared to 56 days at September 30, 2021. Inventory turns decreased to 1.2 times as of September 30, 2022 compared to 1.3 times as of September 30, 2021.

### Investing Activities

Cash flows from investing activities decreased $4.6 million

- Decrease of $4.5 million associated with capital expenditures compared to the prior year period
- Decrease of $1.5 million associated with the payment of a contingent consideration milestone related to an asset acquisition in 2022
- Partially offset by an increase in other investing activities of $1.4 million

### Financing Activities

Cash flows from financing activities increased $4.1 million

- Increase of $8.4 million associated with cash paid in 2021 for the achievement of a revenue-based milestone associated with the Spinal Kinetics acquisition; the milestone payment totaled $15.0 million with a portion of the payment reflected in both operating and financing activities
- Decrease in net proceeds of $3.1 million from the issuance of common shares, primarily related to the exercise of stock options in the prior year period
- Decrease of $2.0 million related to the conclusion of the FITBONE Contract Manufacturing and Supply Agreement with Wittenstein
- Increase of $0.9 million attributable to other financing activities

#### Credit Facilities

As of September 30, 2022, we had no borrowings outstanding under our secured revolving credit facility. In addition, we had no borrowings outstanding under our available lines of credit in Italy, which provide up to an aggregate amount of €5.5 million ($5.4 million). We were in compliance with all required financial covenants as of September 30, 2022.

### Other

For information regarding contingencies, see Note 7 to the Notes to the Unaudited Condensed Consolidated Financial Statements contained herein.

#### Merger Agreement with SeaSpine

On October 10, 2022, Orthofix Medical Inc. (“Orthofix”), through a wholly-owned subsidiary, entered into an Agreement and Plan of Merger (the “Merger Agreement”) with SeaSpine Holdings Corporation (“SeaSpine”). Pursuant to the Merger Agreement, and subject to approval of Orthofix stockholders and SeaSpine stockholders and the satisfaction or waiver of other specified closing conditions, the Orthofix and SeaSpine businesses will combine in an all-stock merger of equals. The Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Merger Agreement, the Company's wholly-owned subsidiary will merge with and into SeaSpine (the “Merger”), with SeaSpine continuing as a wholly-owned subsidiary of Orthofix following the transaction.

The transaction is expected to close in the first quarter of 2023, subject to approval by both companies’ shareholders and customary closing conditions and regulatory approvals. For additional discussion of this matter, see Note 15 of the Notes to the Unaudited Condensed Consolidated Financial Statements.

#### The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”)

In April 2020, we received $13.9 million in funds from the Centers for Medicare and Medicaid Service ("CMS") Accelerated and Advance Payment Program under the CARES Act. Recoupment of amounts received under the CMS Accelerated and Advance Payment Program was completed in the second quarter of 2022.

#### Spinal Kinetics Contingent Consideration

As part of the consideration for the Spinal Kinetics acquisition, we agreed to make contingent milestone payments of up to $60.0 million. One milestone payment, which was for $15.0 million, became due upon FDA approval of Spinal Kinetics’ M6-C artificial cervical disc, which was achieved and paid in 2019. A revenue-based milestone payment, totaling $15.0 million, was achieved and paid in 2021 upon meeting certain net sales targets.

The remaining milestone payment is a revenue-based milestone payment of $30.0 million in connection with future sales of the acquired artificial discs. The fair value of the contingent consideration arrangement was concluded to be zero as of September 30, 2022, as we do not expect to achieve the milestone prior to the deadline of April 30, 2023. For additional discussion of this matter, see Note 6 of the Notes to the Unaudited Condensed Consolidated Financial Statements.

#### Neo Medical Convertible Loan

In October 2020, we entered into a Convertible Loan Agreement (the “Convertible Loan”) with Neo Medical SA, a privately held Swiss-based Medtech company (“Neo Medical”), whereby we loaned CHF 4.6 million ($5.0 million as of the issuance date) to Neo Medical. The loan bears interest at 8.0%, with interest due semi-annually. The Convertible Loan matures in October 2024; however, if a change in control of Neo Medical occurs prior to maturity, the Convertible Loan shall become immediately due upon such event.

#### Related Party Transaction

In February 2021, we entered into a technology assignment and royalty agreement with a medical device technology company partially owned and controlled by the wife of President and Chief Executive Officer, Jon Serbousek, whereby we acquired the intellectual property rights to certain assets for consideration of up to $10.0 million. Consideration was comprised of $1.0 million due at signing and $9.0 million in contingent consideration, dependent upon multiple milestones, such as receipt of 510(k) clearance or the attainment of certain net sales targets. None of the contingent consideration has been achieved as of September 30, 2022.

#### IGEA S.p.A Exclusive License and Distribution Agreement

In April 2021, we entered into an Exclusive License and Distribution Agreement (the “License Agreement”) with IGEA S.p.A (“IGEA”), an Italian manufacturer and distributor of bone and cartilage stimulation systems. Per the terms of the License Agreement, we have the exclusive right to sell IGEA products in the U.S. and Canada. As consideration for the License Agreement, we agreed to pay up to $4.0 million, of which $0.5 million was paid in the second quarter of 2021, with certain payments contingent upon achieving an FDA milestone. We received FDA approval for the AccelStim device in May 2022, triggering an obligation to pay the remaining $3.5 million of consideration, of which $1.5 million was paid in the second quarter of 2022. Of the remaining $2.0 million obligation, $1.0 million is classified within other current liabilities, which is due to be paid on the first anniversary of FDA approval, and $1.0 million is classified within other long-term liabilities, which is due to be paid on the second anniversary of FDA approval. The License Agreement also includes certain minimum purchase requirements.

#### CGBio Co., Ltd. Exclusive License and Distribution Agreement

On July 30, 2022, we entered into a long-term strategic License and Distribution Agreement (the “Agreement”) with CGBio Co., Ltd. (“CGBio”), a developer of innovative, synthetic bone grafts. The agreement grants us the exclusive right to conduct pre-clinical and clinical studies, commercialize, promote, market, and sell the Novosis recombinant human bone morphogenetic protein-2 (rhBMP-2) bone growth materials and other future tissue regenerative solutions in the U.S. and Canada. As consideration, we paid CGBio an upfront payment of $1.4 million with additional payments contingent upon the achievement of specified development milestones.

### Off-balance Sheet Arrangements

As of September 30, 2022, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, cash flows, liquidity, capital expenditures or capital resources that are material to investors.

### Contractual Obligations

There have been no material changes in any of our material contractual obligations as disclosed in our Form 10-K for the year ended December 31, 2021.

### Critical Accounting Estimates

Our discussion of operating results is based upon the condensed consolidated financial statements and accompanying notes. The preparation of these statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Our critical accounting estimates are detailed in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2021. There have been no significant changes to our critical accounting estimates.

### Recently Issued Accounting Pronouncements

See Note 2 of the Notes to the Unaudited Condensed Consolidated Financial Statements for detailed information regarding the status of recently issued or adopted accounting pronouncements. As of September 30, 2022, we do not expect any of the issued Accounting Standards Updates to materially affect our condensed consolidated financial statements upon adoption.

### Non-GAAP Financial Measures

We believe that providing non-GAAP financial measures that exclude certain items provides investors with greater transparency to the information used by senior management in its financial and operational decision-making. We believe it is important to provide investors with the same non-GAAP metrics used to supplement information regarding the performance and underlying trends of our business operations to facilitate comparisons to historical operating results and internally evaluate the effectiveness of our operating strategies. Disclosure of these non-GAAP financial measures also facilitates comparisons of our underlying operating performance with other companies in the industry that also supplement their GAAP results with non-GAAP financial measures.

The non-GAAP financial measures used in this filing may have limitations as analytical tools, and should not be considered in isolation or as a replacement for GAAP financial measures. Some of the limitations associated with the use of these non-GAAP financial measures are that they exclude items that reflect an economic cost that can have a material effect on cash flows.

#### Constant Currency

Constant currency is calculated by using foreign currency rates from the comparable, prior-year period to present net sales at comparable rates. Constant currency can be presented for numerous GAAP measures, but is most commonly used by management to analyze net sales without the impact of changes in foreign currency rates.

#### EBITDA

EBITDA is a non-GAAP metric defined as earnings before interest income (expense), income taxes, depreciation, and amortization. EBITDA is the primary metric used by our Chief Operating Decision Maker in managing the business.

#### Free Cash Flow

Free cash flow is calculated by subtracting capital expenditures from net cash from operating activities. Management uses free cash flow as an important indicator of how much cash is generated or used by our normal business operations, including capital expenditures. Management uses free cash flow as a measure of progress on its capital efficiency and cash flow initiatives.

## Market risk

As filed, 123 characters.

There have been no material changes to our market risks as disclosed in our Form 10-K for the year ended December 31, 2021.

## Controls and procedures

As filed, 1,489 characters.

### Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) designed to provide reasonable assurance that the information required to be disclosed in reports filed or submitted under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. These include controls and procedures designed to ensure that this information is accumulated and communicated to management, including our President and Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Management, with the participation of the President and Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2022. Based on this evaluation, our President and Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 30, 2022.

### Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting, known to the President and Chief Executive Officer or the Chief Financial Officer that occurred for the quarterly period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 19,534 characters.

The following risk factors supplement and should be read in conjunction with those contained in the risk factors disclosed in the “Risk Factors” section of our Form 10-K for the year ended December 31, 2021, except as follows.

### Risks Related to the Pending Merger with SeaSpine

*The merger is subject to conditions, some or all of which may not be satisfied, or completed on a timely basis, if at all. Failure to complete the merger could have material adverse effects on Orthofix and SeaSpine.*

The completion of the merger is subject to a number of conditions, including, among other things, the receipt of the Orthofix stockholder approval and the SeaSpine stockholder approval and receipt of certain regulatory approvals, which make the completion and timing of the merger uncertain. The failure to satisfy all of the required conditions could delay the completion of the merger for a significant period of time or prevent it from occurring at all. There can be no assurance that the conditions to the completion of the merger will be satisfied or waived or that the merger will be completed.

If the merger is not completed, each of Orthofix and SeaSpine may be materially adversely affected and, without realizing any of the benefits of having completed the merger, will be subject to a number of risks, including the following:

- the market price of Orthofix common stock or SeaSpine common stock could decline;
- Orthofix or SeaSpine could owe a substantial termination fee to the other party in specified circumstances;
- if the merger agreement is terminated and the Orthofix Board or the SeaSpine Board seeks another business combination, Orthofix stockholders or SeaSpine stockholders, as applicable, cannot be certain that Orthofix or SeaSpine, as applicable, will be able to find a party willing to enter into a transaction on terms equivalent to or more attractive than the terms that the other party has agreed to in the merger agreement;
- time and resources, financial and other, committed by Orthofix’s and SeaSpine’s management to matters relating to the merger could otherwise have been devoted to pursuing other beneficial opportunities;
- Orthofix or SeaSpine may experience negative reactions from the financial markets or from its customers, suppliers or employees; and
- Orthofix and SeaSpine will each be required to pay its costs relating to the merger, such as legal, accounting, financial advisory and printing fees, whether or not the merger is completed (subject to certain exceptions).

In addition, if the merger is not completed, each of Orthofix and SeaSpine could be subject to litigation related to any failure to complete the merger or related to any enforcement proceeding commenced against such party to perform its obligations under the merger agreement. Any of these risks could materially and adversely impact Orthofix’s or SeaSpine’s ongoing business, financial condition, financial results and stock price.

Similarly, delays in the completion of the merger could, among other things, result in additional transaction costs, loss of revenue or other negative effects associated with delay and uncertainty about completion of the merger and could materially and adversely impact Orthofix’s and SeaSpine’s ongoing business, financial condition, financial results and stock price following the completion of the merger.

*The merger is subject to the expiration or termination of applicable waiting periods and the receipt of approvals, consents or clearances from several regulatory authorities that may impose conditions that could have an adverse effect on Orthofix, SeaSpine or the combined company or, if not obtained, could prevent completion of the merger.*

Before the merger may be completed, any applicable waiting period (and any extension thereof) under the HSR Act relating to the completion of the merger must have expired or been terminated and any authorization or consent from a governmental authority required to be obtained with respect to the merger under certain other applicable foreign regulatory laws must have been obtained. In deciding whether to grant the required regulatory authorization or consent, the relevant governmental entities will consider the effect of the merger within their relevant jurisdiction, including, among other things, the impact on the parties’ respective customers and suppliers. The terms and conditions of the authorizations and consents that are granted, if any, may impose requirements, limitations or costs or place restrictions on the conduct of the combined company’s business or may materially delay the completion of the merger.

Under the merger agreement, Orthofix and SeaSpine have agreed to use their respective reasonable best efforts to obtain such authorizations and consents, and each of Orthofix and SeaSpine has agreed take all actions, and to do promptly, or cause to be done, and to assist and cooperate with each other in doing, all things necessary, proper or advisable under applicable laws to carry out the intent and purposes of the merger agreement and to consummate the transactions contemplated by the merger agreement. However, Orthofix’s and SeaSpine’s obligations to take such actions are subject to limitations, including that neither Orthofix nor SeaSpine will be required to divest, sell, dispose of, or license or agree to divest, sell, dispose of, or license any assets, businesses, rights or operations.

In addition, at any time before or after the completion of the merger, and notwithstanding the termination of applicable waiting periods, the applicable U.S. or foreign regulatory authorities or any state attorney general could take such action under antitrust or applicable foreign investment laws as such party deems necessary or desirable in the public interest. Such action could include, among other things, seeking to enjoin the completion of the merger or seeking divestiture of substantial assets of the parties. In addition, in some circumstances, a third party could initiate a private action challenging, seeking to enjoin, or seeking to impose conditions on the merger. Orthofix and SeaSpine may not prevail and may incur significant costs in defending or settling any such action.

There can be no assurance that the conditions to the completion of the merger set forth in the merger agreement relating to applicable regulatory laws will be satisfied.

*The merger agreement contains provisions that limit Orthofix’s and SeaSpine’s ability to pursue alternatives to the merger, could discourage a potential competing transaction counterparty of Orthofix or SeaSpine from making a favorable alternative transaction proposal, and provide that, in specified circumstances, each of Orthofix and SeaSpine would be required to pay a termination fee.*

The merger agreement contains provisions that make it more difficult for SeaSpine to sell its business to a party other than Orthofix, or for Orthofix to sell its business. These provisions include a general prohibition on each party soliciting any acquisition proposal. Further, there are only limited exceptions to each party’s agreement that its board of directors will not withdraw or modify in a manner adverse to the other party the recommendation of its board of directors in favor of the adoption of the merger agreement, in the case of SeaSpine, or the approval of the stock issuance, in the case of Orthofix, and the other party generally has a right to attempt to match any acquisition proposal that may be made. However, at any time prior to the adoption of the merger agreement by SeaSpine stockholders, in the case of SeaSpine, or the approval of the Orthofix share issuance proposal by Orthofix stockholders, in the case of Orthofix, such party’s board of directors is permitted to make an adverse recommendation change if it determines in good faith that the failure to take such action would be reasonably likely to be inconsistent with its fiduciary duties under applicable law.

In some circumstances, upon termination of the merger agreement, SeaSpine would be required to pay a termination fee of approximately $10.6 million to Orthofix, and in some circumstances, upon termination of the merger agreement, Orthofix would be required to pay a termination fee of approximately $13.7 million to SeaSpine, each as contemplated by the merger agreement.

The parties believe these provisions are reasonable and not preclusive of other offers, but these restrictions might discourage a third party that has an interest in acquiring all or a significant part of either SeaSpine or Orthofix from considering or proposing an acquisition proposal, even if that party was prepared to pay consideration with a higher per-share value than the currently proposed merger consideration, in the case of SeaSpine, or that party was prepared to enter into an agreement that may be favorable to Orthofix or its stockholders, in the case of Orthofix. Furthermore, the termination fees described above may result in a potential competing acquirer proposing to pay a lower per-share price to acquire the applicable party than it might otherwise have proposed to pay because of the added expense of the termination fee that may become payable by such party in certain circumstances.

*The exchange ratio is fixed and will not be adjusted in the event of any change in either Orthofix’s or SeaSpine’s stock price.*

Upon completion of the merger, each issued and outstanding share of SeaSpine common stock (other than excluded shares) will be converted into the right to receive the merger consideration, which is equal to 0.4163 fully paid and nonassessable shares of Orthofix common stock (and, if applicable, cash in lieu of fractional shares). This exchange ratio was fixed in the merger agreement and will not be adjusted for changes in the market price of either Orthofix common stock or SeaSpine common stock.

It is impossible to accurately predict the market price of Orthofix common stock at the completion of the merger and, therefore, impossible to accurately predict the market value of the shares of Orthofix common stock that SeaSpine stockholders will receive in the merger. The market price for Orthofix common stock may fluctuate both prior to the completion of the merger and thereafter for a variety of reasons, including, among others, general market and economic conditions, the demand for Orthofix’s or SeaSpine’s products and services, changes in laws and regulations, other changes in Orthofix’s and SeaSpine’s respective businesses, operations, prospects and financial results of operations, market assessments of the likelihood that the merger will be completed, and the expected timing of the merger. Many of these factors are beyond Orthofix’s and SeaSpine’s control. As a result, the market value represented by the exchange ratio will also vary.

*Each party is subject to business uncertainties and contractual restrictions while the merger is pending, which could adversely affect each party’s business and operations.*

In connection with the pendency of the merger, it is possible that some customers, suppliers and other persons with whom Orthofix and/or SeaSpine has a business relationship may delay or defer certain business decisions or might decide to seek to terminate, change or renegotiate their relationships with Orthofix or SeaSpine, as the case may be, as a result of the merger or otherwise, which could negatively affect Orthofix’s or SeaSpine’s respective revenues, earnings and/or cash flows, as well as the market price of Orthofix common stock or SeaSpine common stock, regardless of whether the merger is completed.

Under the terms of the merger agreement, each of Orthofix and SeaSpine is subject to certain restrictions on the conduct of its business prior to completing the merger, which may adversely affect its ability to execute certain of its business strategies, including the ability in certain cases to modify or terminate contracts, acquire or dispose of assets, incur indebtedness, pay dividends, incur capital expenditures or settle claims. Such limitations could adversely affect each of Orthofix’s and SeaSpine’s business and operations prior to the completion of the merger.

Each of the risks described above may be exacerbated by delays or other adverse developments with respect to the completion of the merger.

*Completion of the merger may trigger change in control or other provisions in certain distributor, customer and other agreements to which Orthofix or SeaSpine is a party, which may have an adverse impact on the combined company’s business and results of operations following completion of the merger.*

The completion of the merger may trigger change in control and other provisions in certain agreements to which Orthofix or SeaSpine is a party. If Orthofix or SeaSpine is unable to negotiate waivers of those provisions, counterparties may exercise their rights and remedies under the agreements, including terminating the agreements or seeking monetary damages or equitable remedies. Even if Orthofix and SeaSpine are able to negotiate consents or waivers, the counterparties may require a fee for such waivers or seek to renegotiate the agreements on terms less favorable to Orthofix or SeaSpine. Any of the foregoing or similar developments may have an adverse impact on the combined company’s business and results of operations following completion of the merger.

*Uncertainties associated with the merger may cause a loss of management personnel and other key employees, which could adversely affect the future business and operations of the combined company following completion of the merger.*

Orthofix and SeaSpine are dependent on the experience and industry knowledge of their officers and other key employees to execute their business plans. The combined company’s success after the completion of the merger will depend in part upon the ability of the combined company to retain certain key management personnel and employees of Orthofix and SeaSpine. Prior to the completion of the merger, current and prospective employees of Orthofix and SeaSpine may experience uncertainty about their roles following the completion of the transactions, which may have an adverse effect on the ability of each of Orthofix and SeaSpine to attract or retain key management and other key personnel. In addition, no assurance can be given that the combined company, after the completion of the merger, will be able to attract or retain key management personnel and other key employees to the same extent that Orthofix and SeaSpine have previously been able to attract or retain their own employees.

*Orthofix’s executive officers and directors and SeaSpine’s executive officers and directors have interests in the merger that may be different from, or in addition to, Orthofix’s stockholders’ and SeaSpine’s stockholders’ interests.*

When considering the recommendation of the Orthofix Board that Orthofix stockholders approve the Orthofix share issuance proposal and the recommendation of the SeaSpine Board that the SeaSpine stockholders approve the SeaSpine merger proposal, such stockholders should be aware that certain directors and executive officers of Orthofix and directors and executive officers of SeaSpine have certain interests in the merger that may be different from, or in addition to, the interests of such stockholders. The Orthofix Board was aware of the interests of Orthofix’s directors and executive officers, the SeaSpine Board was aware of the interests of SeaSpine’s directors and executive officers, and each board considered such interests, among other matters, when it approved the merger agreement and in making its recommendations to its stockholders. Additional interests of the executive officers of Orthofix in the merger include certain performance stock unit achievement rights and certain post separation cash severance and equity acceleration rights, in each as a result of the Orthofix Board’s determination to treat the transaction as a “Change in Control” under applicable agreements and equity plans. Additional interests of the directors include continued service on the board of the combined company or certain equity acceleration rights in the event that the director is not continuing. Additional interests of the directors and executive officers of SeaSpine in the merger include (i) the payment of certain severance and other benefits upon a qualifying termination of employment or service following the completion of the merger, (ii) continued employment or service on the board of the combined company and (iii) the continued provision of indemnification and insurance coverage for current and former directors and executive officers of SeaSpine in accordance with the merger agreement. As a result of these interests, these directors (as applicable) and executive officers might be more likely to support and to vote in favor of the proposals described in this joint proxy statement/prospectus than if they did not have these interests. Orthofix stockholders and SeaSpine stockholders should consider whether these interests might have influenced these directors (as applicable) and executive officers to recommend adopting the merger agreement.

*Following the merger, the composition of the combined company board of directors will be different than the composition of the current Orthofix Board or the current SeaSpine Board.*

The Orthofix Board currently consists of nine directors and the SeaSpine Board currently consists of nine directors. Upon completion of the merger, the board of directors of the combined company will consist of nine directors, including five directors designated by Orthofix and four directors designated by SeaSpine. This new composition of the board of directors of the combined company may affect the future decisions of the combined company.

### Other Risk Factors

*The conflict between Russia and Ukraine may continue to cause global economic instability and potentially disrupt supply chains.*

In February 2022, Russia unlawfully invaded Ukraine, creating an ongoing humanitarian and global security crisis. In response, the U.S. and many other countries have imposed robust sanctions on Russia and may impose additional sanctions in the future. The ongoing invasion has caused significant damage and disruption to various aspects of the global economy. We have never conducted any meaningful business within Russia, and do not believe that the invasion will have material direct effects on our business or operations. However, we cannot predict the broader and longer-term consequences of this conflict or the sanctions imposed in response, and such consequences could include, among other things, general disruptions to global finance markets, exchange rates, and worldwide supply chains. Geopolitical instability and uncertainty resulting from the invasion could potentially have a negative impact on our ability to sell to, ship products to, collect payments from, and support customers in certain regions based on trade restrictions, embargoes and export control law restrictions, and logistics restrictions. These considerations could adversely affect our costs, risks, and efficiencies related to our supply chain and logistics. The potential effects of the conflict between Russia and Ukraine also could affect many of the other risk factors described in Item 1A, Risk Factors, in our Annual Report on Form 10-K for the year ended December 31, 2021.

Filed Nov 3, 2022.
Source: SEC EDGAR, the filing index for accession 0000950170-22-021538. Last ingested by Listed: Nov 13, 2026, 17:00 ET. No prices; not investment advice.
